000			a
999			_c18273 _d18273
003			OSt
005			20221118113328.0
008			221118b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_919140 _aChatterjee, Suparna
245			_aUpdate of antispike severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) monoclonal antibodies
250			_aVol.54(1), Jan-Feb
260			_aMumbai _bWolter Kluwer _c2022
300			_a51-57p.
520			_aThe use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS‑CoV‑2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID‑19 patients with mild‑to‑moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost‑benefit profile shall provide useful information to the scientific community and patients.
650		0	_94774 _aPHARMACOLOGY
700			_919141 _aChoudhury, Shouvik
773	0		_dAndheri - Mumbai Wolters Kluwer India Private Limited _x0253-7613 _tIndian Journal of Pharmacology
856			_uhttps://www.ijp-online.com/temp/IndianJPharmacol54151-2105218_055052.pdf _yClick here
942			_2ddc _cAR